866-997-4948(US-Canada Toll Free)

Myocardial Ischemia - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 64 Pages

Myocardial Ischemia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Ischemia - Pipeline Review, H1 2017, provides an overview of the Myocardial Ischemia (Cardiovascular) pipeline landscape.

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocardial Ischemia - Overview
Myocardial Ischemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocardial Ischemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocardial Ischemia - Companies Involved in Therapeutics Development
Angionetics Inc
Bayer AG
Cellmid Ltd
CohBar Inc
Lixte Biotechnology Holdings Inc
NoNO Inc
Omniox Inc
Pathfinder Cell Therapy Inc
Shire Plc
Symic Biomedical Inc
ViroMed Co Ltd
Myocardial Ischemia - Drug Profiles
AB-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AntimiR-199a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-606583 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMK-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-80317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMX-4.80 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pathfinder Cells - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMC-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Myocardial Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocardial Ischemia - Dormant Projects
Myocardial Ischemia - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Myocardial Ischemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Myocardial Ischemia - Pipeline by Angionetics Inc, H1 2017
Myocardial Ischemia - Pipeline by Bayer AG, H1 2017
Myocardial Ischemia - Pipeline by Cellmid Ltd, H1 2017
Myocardial Ischemia - Pipeline by CohBar Inc, H1 2017
Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Myocardial Ischemia - Pipeline by NoNO Inc, H1 2017
Myocardial Ischemia - Pipeline by Omniox Inc, H1 2017
Myocardial Ischemia - Pipeline by Pathfinder Cell Therapy Inc, H1 2017
Myocardial Ischemia - Pipeline by Shire Plc, H1 2017
Myocardial Ischemia - Pipeline by Symic Biomedical Inc, H1 2017
Myocardial Ischemia - Pipeline by ViroMed Co Ltd, H1 2017
Myocardial Ischemia - Dormant Projects, H1 2017
Myocardial Ischemia - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Myocardial Ischemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *